These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16684431)

  • 1. Initial experience with teriparatide in the United States.
    Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
    Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient experience with a new teriparatide delivery device.
    Dore RK; Feldman RG; Taylor KA; See K; Dalsky GP; Warner MR
    Curr Med Res Opin; 2009 Oct; 25(10):2413-22. PubMed ID: 19656016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating osteoporosis with teriparatide: many unknowns?
    Shukla VK
    Issues Emerg Health Technol; 2003 Nov; (51):1-4. PubMed ID: 14610756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
    Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
    [No Abstract]   [Full Text] [Related]  

  • 6. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
    Tashjian AH; Gagel RF
    J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
    Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
    Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H; Hamaya E; Yamamoto T
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF; Hamdy NA; Netelenbos JC
    Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriparatide for severe osteoporosis.
    Cappuzzo KA; Delafuente JC
    Ann Pharmacother; 2004 Feb; 38(2):294-302. PubMed ID: 14742769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
    Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The teriparatide in the treatment of severe senile osteoporosis.
    Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of teriparatide and TNFalpha blockade: safety.
    Migliore A; Massafra U; Capuano A; Martin SM
    Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):18-20. PubMed ID: 18180602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
    Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
    Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
    Yamamoto T; Hamaya E; Sowa H
    Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.